Pharmacyclics is a biopharmaceutical company founded in April 1991 discovering and developing medications to treat and alleviate the suffering of oncology patients.
Headquartered in Sunnyvale, California Pharmacyclics’ main product is called IMBRUVICA™ and is a prescription medicine indicated for treating people with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia who have received at least one prior treatment. IMBRUVICA™ has just recently in October 2014 been approved for European use of two blood cancers.
The company also has a healthy pipeline of products budding well in its research and development department. Of all the products 50% have reached phase III development and the other half at least phase II development. All of the products are indicated for oncology however the company has one product that is targeting autoimmune disorders.
Starting with the aim of creating treatments for cancer patients Pharmacyclics set up over 20 years ago as a small start-up company in California, 4 years later it filed to become a public company raising significant funds through high share sales. The company built up its foundations further and in 2006 it acquired some major biological compounds from Celera, one of which was a BTK inhibitor, a HDAC inhibitor and a factor / VIII a inhibitor. Several other partnerships with major pharma companies rolled on after this, one of which involved Janssen, the BTK inhibitor and $975million.
As a functioning company today, Pharmacyclics has just become a new entry into the biotechnology top 50 list by company revenue.
Recent partnering in the news
As well as its past partnerships with major pharma companies Pharmacyclics has been the subject of many deals in this Q3 2014 already. Firstly its partnership with Janssen has just grown as IMBRUVICA™ has just been approved for two new blood cancers, Janssen will become the marketing authorization holder for Europe.
Pharmacyclics has also just formed a pharma alliance with Roche to evaluate the safety, tolerability and preliminary efficacy of IMBRUVICA in combination with GAZYVA which is a new antibody that attacks targeted cells in patients with non-Hodgkin Lyphoma (NHL) and Chronic Lymphocytic Leukaemia.
Finally and sadly Servier who tied up with Pharmacyclics to develop the oncology focused inhibitor Abexinostat in 2009 has just last month in September decided to abandon the collaboration leaving Pharmacyclics left with an unpartnered drug in the middle of phase II trials. It is uncertain what will happen with this drug the company is yet to decide what it will do.
Pharmacyclics is often present at a large number of partnering events throughout the year. Partnering events are a great place to meet lots of potential partners face to face in a short space of time.
Events with Pharmacyclics presence include but are not limited to:
- BIO International Convention and Business Forum
- BioEurope / BioEurope Spring
For a full list of forthcoming partnering events where you could meet with Pharmacyclic’s in person visit Current Partnering’s Event calendar.
Contacting Pharmacyclics for partnering
Pharmacyclics can be contacted in relation to partnering through a number of channels. Here is a list of the most common channels:
Partnering events: face to face contact is generally considered the most effective form of contact. Partnering events not only allow face to face contact but also contact with multiple companies for the price of one flight and hotel reservation. This benefit makes partnering events the most cost effective method of making personal introductions as a start point for partnering discussions.
See Current Partnering’s event calendar for details of forthcoming events.
Direct contact: there are several sources of direct contact with Pharmacyclic’s business development team
- Phone: Picking up the phone and speaking with an individual is the best form of non-face to face contact as it allows your name and voice to be remembered and associated with an opportunity.
- Email: Sending an email is another good way of making contact. Ideally, research the individual responsible for the therapy/technology area being targeted and get in touch website for details.
- LinkedIn: Business to business contact is increasingly taking place via LinkedIn, the global online networking channel.
Many of Pharmacyclic’s business development executives have LinkedIn profiles and can be found by viewing the company’s profile. Visit Pharmacyclic’s LinkedIn page here.
Opportunity submission form: the least favourable channel but worth using if you do not have access to the other channels mentioned above. This is the form available on the Pharmacyclic’s Pharmaceutical website for potential partnering opportunities.
Our report provides more detailed insight into the details of each deal. See: Partnering Agreements with Pharmacyclics 2009-2014
Pharmacyclics partnering at Current Agreements
Full details on each deal can be found at CurrentAgreements (subscription required)
No M&A activity for Pharmacyclics
Available reports from Current Partnering
Report: Partnering Deals and Alliances with Big Biotech
Available resources for deal coverage for Pharmacyclics
Read: more on Pharmacyclics company profile, recent partnering, M&A and financing news and articles
View: Current Partnering Insight’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering Insight’s M&A Scorecard – view top life science M&A deals by value
View: Current Partnering Insight’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Partnering Activity – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Partnering Activity – latest trends in big pharma deal making activity
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk